SimcoDerm Clinical Trials

09/05/2025

👀 What’s next for HS treatments?
We’ve scanned the latest reports so you don’t have to. Here’s what’s happening in clinical trials for HS medications this quarter.
Full update: https://simcoderm.com/2025/09/2025-q2-hs-research-update/

09/04/2025

Society spends a lot of time talking about current issues. But it’s easy to forget that billions of people live every day with substantial levels of pain. That’s why, in September, we raise awareness of pain.

💡 Chronic pain is more than “just discomfort”:
• 1 in 3 seniors in Canada lives with it.
• Up to 1 in 3 kids do, too.
• It costs our country as much as $60 billion every year.

For many — especially women, veterans, and Indigenous Peoples — pain is not only physical. It’s deeply tied to emotional health and social inequality.

✨ Raising awareness means reminding society that pain is real, life-altering, and worthy of action.
👉 Share this message. Together, we can break the silence around pain. 💙.

08/28/2025

Progress

Systematic review: Hidradenitis suppurativa (HS) is linked to significant psychological comorbidities, including disordered eating behaviors. https://ja.ma/4oVXoD2

08/19/2025

A useful perspective on treating atopic dermatitis.

🎥Balancing efficacy and safety in atopic dermatitis treatment: Discover how clinicians navigate JAK inhibitor therapy, from patient selection to risk management: https://hubs.li/Q03DgqCC0

08/19/2025

Sometimes medical care doesn't offer a great solution to skin disease. A severe case of eczema, for example, can continue to cause stress and burden despite the best efforts of dermatologists.

That's why we run clinical trials. It is the scientific way to determine the safety and effectiveness of new treatments. If you want to help us research potential new therapies for skin conditions call us at (289)763-8666 or visit www.simcoderm.com/clinicaltrials.

08/05/2025

"New study in the Journal of American Academy of Dermatology explores tunnel-targeted antimicrobial gel for HS treatment"
It's refreshing to see motion in the world of HS treatment. Looking forward to further study!

💜 New study in Journal of the American Academy of Dermatology (JAAD) explores tunnel-targeted antimicrobial gel for HS treatment bit.ly/HSFnews

🙌 Shout out to University of Miami Miller School of Medicine researchers including HSF President, Dr. Hadar Lev-Tov, for this work that offers new insights into localized therapies for HS.

07/28/2025

🎥IL-17 Inhibitors can make a significant impact for patients with psoriasis. Hear from top dermatologists as they break down efficacy, safety, and real-world application. Watch here: https://hubs.li/Q03z1lz-0

07/16/2025

Have you ever been confused reading about a skin problem? One line you're being told about a pustule, and the next they call it a lesion. We put together this glossary of bump names to clear up some of the confusion.

Follow the link to learn more: 🔗🔗 https://simcoderm.com/2025/06/nodule-vs-papule-a-glossary-of-dermatologic-skin-lesions/

07/16/2025

How are Janus kinase (JAK) inhibitors changing the treatment landscape for atopic dermatitis?

In this insightful Peers and Perspectives®, Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, explore the groundbreaking role of JAK inhibitors in delivering faster, deeper, and more durable responses than traditional biologics, especially for patients who have struggled to achieve both skin clearance and itch relief.

With the AHEAD recommendations setting new benchmarks for optimal treatment targets, JAK inhibitors are emerging as a vital option for dermatologists aiming to elevate patient care and outcomes.

Don’t miss this opportunity to hear from leading experts on the evolving strategies in AD management.

Watch Now: https://hubs.li/Q03xjbT40

07/02/2025

Hidradenitis Suppurativa (HS) is far too harmful to keep the status quo. SimcoDerm Medical & Surgical Dermatology Centre is recruiting participants for an innovative clinical study that could lead to a better treatment.

If you are 18-80 years old with moderate-severe HS in at least two distinct anatomical regions, you might qualify for the trial at no cost. Time and travel may be compensated for qualified participants.

You could receive the investigational drug for up to a year and will be seen frequently by a leading dermatologist specialized in HS care.

Your commitment can help others with HS by pushing research forward so that one day we might be able to give them easier options that help.

Apply today on our website or call us at #289-763-8666
https://simcoderm.com/clinicaltrials-hidradenitissuppurativa/

06/30/2025

Seems relevant 😓☀️☀️🌎

Dr. Cheyrl Rosen, MD, FRCPC, presents on "The Importance of Sun Safety" during our Melanoma Awareness Month Webinar, held on May 28, 2025.Watch, pause, and r...

06/28/2025

Visit the page for more information!
https://simcoderm.com/ca43-j2t-mc-kgcd-for-chronic-hand-and-foot-eczema/